Identifying CLL antigens for future combinational therapy

Abstract

In this issue of Blood, Dubovsky et al use novel methodology to identify lymphocyte cytosolic protein-1 (LCP1) as a putative tumor-associated antigen, Ag (TAA) that may play a critical role in regulating CLL cell homing to the leukemia niche.1 Their translational research approach further shows that kinase inhibitors (KIs) have the potential to block LCP1 activation, which raises the possibility that these drugs might be effectively combined with LCP1-targeted biological therapies. © 2013 by The American Society of Hematology.